Trials / Completed
CompletedNCT02191254
Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 245 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antistax® | |
| DRUG | Placebo |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2004-10-01
- First posted
- 2014-07-16
- Last updated
- 2014-07-16
Source: ClinicalTrials.gov record NCT02191254. Inclusion in this directory is not an endorsement.